If approved by the FDA, Flibanserin will be the first drug on the market for women who report to have a lack of sexual drive. Soon will be presented a new proposal for approval to the FDA.
Flibanserin is a 5-HT1A receptor agonist and 5-HT2A receptor antagonist that had initially been investigated as an antidepressant.
Evidence from a variety of sources suggests that the neurotransmitter serotonin may have a role in Hypoactive sexual desire disorder by acting excessively as a sexual satiety signal. Serotonergic agents such as the selective serotonin reuptake inhibitors (SSRIs) inhibit all phases of sex including desire, arousal, and orgasm.
Addition of the 5-HT1A receptor partial agonist, buspirone, to SSRI treatment has been shown to counteract these negative sexual side effects. The 5-HT1A receptor mediates inhibitory neurotransmission.
Flibanserin, as a full 5-HT1A receptor agonist, is presumed to have similar or even more pronounced pro-sexual effects as buspirone.
Stimulation of the serotonin 5-HT2A receptor in male rodents has been associated with decreased sexual behavior. Thus, 5-HT2A antagonism is theorized to have pro-sexual effects.
Supporting this notion is the fact that nefazodone, an SSRI with inherent 5-HT2A receptor antagonist activity,
has fewer negative sexual side effects than other SSRIs without such activity.
Flibanserin has been shown to block central 5-HT2A receptors, and thus might reverse sexual inhibition caused by an excess of serotonin activity in the brain.
Although flibanserin’s effect is believed to be related to its activity at the 5-HT1A and 5-HT2A receptors, its mechanism of action in the treatment of HSDD is unknown.
http://www.fda.gov/downloads/Advisor.../UCM215437.pdf





